Changes in eicosapentaenoic acid and docosahexaenoic acid and risk of cardiovascular events and atrial fibrillation: A secondary analysis of the OMEMI trial.
Peder Langeland MyhreAre A KalstadSjur H TveitKristian LaakeErik B SchmidtPal SmithDennis W T NilsenArnljot TveitSvein SolheimHarald ArnesenIngebjørg SeljeflotPublished in: Journal of internal medicine (2022)
Greater on-treatment increases in EPA were associated with lower risk of MACE and higher risk of new-onset AF. These data suggest that the cardiovascular effects of increasing n-3 PUFA levels through supplements are complex, involving both potential benefits and harm.
Keyphrases
- cardiovascular events
- atrial fibrillation
- coronary artery disease
- cardiovascular disease
- heart failure
- clinical trial
- study protocol
- left atrial
- catheter ablation
- left atrial appendage
- oral anticoagulants
- percutaneous coronary intervention
- direct oral anticoagulants
- fatty acid
- electronic health record
- big data
- randomized controlled trial
- climate change
- human health
- phase ii
- artificial intelligence
- risk assessment
- venous thromboembolism
- acute coronary syndrome